Eric J. Sieczka

Eric J. Sieczka is the Chairman, President and CEO of Epsilon Imaging. Mr. Sieczka has spent over 20 years commercializing technologies and building Michigan-based enterprises. His experience ranges from technology creation, product development and operations management to financing and strategic transactions. He is also the co-founder, and sits on the Board, of Pixel Velocity Incorporated, another investor-backed early stage technology business and the former parent company of Epsilon Imaging. Prior to starting Pixel Velocity and Epsilon Imaging, Mr. Sieczka was the co-founder and Vice President of Operations for EOTech Inc, where he built the operations from a start-up product concept, into a world-class, fully integrated manufacturing facility with optical, electrical, and mechanical design capabilities servicing markets around the globe. Prior to his departure, Mr. Sieczka helped orchestrate the successful sale of EOTech to L-3 Communications (a $10B publicly traded defense contractor). Mr. Sieczka has eight patents covering an array of electro-optic technologies. He holds a BSEE degree from Kettering Institute and an MBA from the Ross School of Business at the University of Michigan.

Philip M. Croxford is an experienced medical device CEO who has had a track record of delivering exceptional commercial and financial performance across a wide range of modalities and international markets. Most recently, he was President and CEO of an early stage breast cancer diagnostic company, Gamma Medica, Inc. Prior, he was Global President and CEO at LifeCell, a bio-tissue technology company, sold by APAX Partners, a private equity firm, to Allergan. He has also held similar level positions with Getinge AB, Draeger Medical, Arrow International Inc. (now Teleflex), Johnson & Johnson and Smith & Nephew.  Mr. Croxford has had extensive early stage, PE owned and “midcap” sized organization experience, with a track record of developing commercialization plans that delivered a substantial change in top and bottom line growth.  He is also a board member of Vital Therapies Inc. [VTL – NASDAQ], a biotech company that has developed an extra-corporeal liver assist therapy to treat terminal and chronic liver disease.  He was awarded a BSc(Hons) in Pharmacy from the University Manchester, England and a MBA from Edinburgh Business School, Heriot Watt University, UK.  He is also member of the Pharmaceutical Society of Great Britain and a Chartered Member of the Institute of Marketing, UK.

Thomas C. Kinnear

Thomas C. Kinnear is J. Maynard Phelps Professor of Business and Marketing at the Ross School of Business at the University of Michigan. He was the founding Executive Director of Samuel Zell and Robert H. Lurie Institute for Entrepreneurial Studies, a position he held for 14 years. He has received awards from the University of Michigan for teaching excellence and service to the University. He previously held a faculty appointment at the University of Western Ontario, and visiting appointments at Harvard University, Stanford University, and the European Management Institute (INSEAD) at Fontainebleau, France. His teaching and research interests are in the areas of entrepreneurial studies, strategic marketing planning, marketing and public policy, and market-based management. He is co-author of several books including Modern Marketing Research, (Thomson) and Principles of Marketing (Harper Collins). He is CEO and Chair of the Board of Directors of the Venture Michigan Corporation, a $200 million venture capital fund of funds, and is a Director and the former Chair of the American Marketing Association. He is active in the entrepreneurial community as a co-founder, advisor, angel investor, and Board member of several startup companies. He is also a member of the investment committee for EDF Ventures and Chairs this committee for Arboretum Ventures. Dr. Kinnear holds an undergraduate degree and LLD (honoris causa) from Queen’s University at Kingston, Ontario, an MBA from Harvard University, and a Ph.D. in Business Administration from the University of Michigan.

Matthew O’Donnell, Ph.D. Following undergraduate, graduate, and post-doctoral training at Notre Dame and Washington University in St. Louis, Dr. O’Donnell joined General Electric Corporate Research and Development Center in Schenectady, NY in 1980, where he worked on medical electronics, including MRI and ultrasound imaging systems. In 1990, he moved to University of Michigan in Ann Arbor, MI where he held appointments in Electrical Engineering & Computer Science and in Biomedical Engineering.  In 1998, he was named the Jerry W. and Carol L. Levin Professor of Engineering. From 1999-2006 he also served as Chair of the Biomedical Engineering Department. In 2006 he moved to the University of Washington in Seattle, WA where he was the Frank and Julie Jungers Dean of Engineering from 2006-2012. He is now Frank and Julie Jungers Dean Emeritus and a Professor of Bioengineering at the University of Washington. His most recent research has explored new imaging modalities, including elasticity imaging, in vivo microscopy, optoacoustic devices, photoacoustic contrast agents for molecular imaging and therapy, laser ultrasound systems, and catheter-based devices. He has won numerous awards, including the Distinguished Alumni Award from the University of Notre Dame, the Achievement and Rayleigh Awards from the IEEE-UFFC Society, the William J. Morlock Award for Excellence in Biomedical Technology from the IEEE-EMBS Society, and the IEEE Biomedical Engineering Award. He is a fellow of the IEEE and AIMBE and is an elected member of the Washington State Academy of Sciences and the National Academy of Engineering.

David J. Romenesko is Founder and President of Tempo Investment Advisors, established in 1986, with offices in Midland MI, and Victoria MN, a suburb of Minneapolis. The firm provides Financial Planning and manages greater than $90 million for client families in 18 states. Many of these clients are investors in Epsilon Imaging as well as a number of other early stage tech companies; some of which have had IPOs or buy outs. Mr. Romenesko has been an active Angel Investor since 2011 and has invested in 28 different companies.Prior to Angel Investing, Mr. Romenesko was a scientist at Dow Corning in Silicone New Ventures for 31 years.